相似文献
1
Defining efficacy in the treatment of overactive bladder syndrome.
Rev Urol. 2009 Fall;11(4):196-202.
2
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0.
3
Treatments for overactive bladder: focus on pharmacotherapy.
J Obstet Gynaecol Can. 2012 Nov;34(11):1092-1101. doi: 10.1016/S1701-2163(16)35440-8.
4
Impact of solifenacin on diary-recorded and patient-reported urgency in patients with severe overactive bladder (OAB) symptoms.
Curr Med Res Opin. 2010 Oct;26(10):2277-85. doi: 10.1185/03007995.2010.509582.
5
Clinical value of a patient-reported goal-attainment measure: the global development of self-assessment goal achievement (SAGA) questionnaire for patients with lower urinary tract symptoms.
Neurourol Urodyn. 2014 Jan;33(1):90-4. doi: 10.1002/nau.22377. Epub 2013 Feb 19.
6
Overactive bladder symptom severity, bother, help-seeking behavior, and quality of life in patients with type 2 diabetes: a path analysis.
Health Qual Life Outcomes. 2018 Jan 2;16(1):1. doi: 10.1186/s12955-017-0829-z.
7
Patient-reported outcomes in the setting of a randomized control trial on the efficacy of transcutaneous stimulation of the posterior tibial nerve compared to percutaneous stimulation in idiopathic overactive bladder syndrome.
Neurourol Urodyn. 2021 Jan;40(1):295-302. doi: 10.1002/nau.24554. Epub 2020 Oct 29.
8
Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
BJU Int. 2014 Sep;114(3):418-26. doi: 10.1111/bju.12678. Epub 2014 Jul 1.
9
Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study).
BJU Int. 2015 Oct;116(4):612-22. doi: 10.1111/bju.13068. Epub 2015 Apr 23.
10
Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Int J Clin Pract. 2008 Jun;62(6):925-31. doi: 10.1111/j.1742-1241.2008.01778.x.
引用本文的文献
1
Barriers and facilitators to overactive bladder therapy adherence.
Neurourol Urodyn. 2022 Nov;41(8):1983-1992. doi: 10.1002/nau.24936. Epub 2022 May 5.
2
Updating the evidence on drugs to treat overactive bladder: a systematic review.
Int Urogynecol J. 2019 Oct;30(10):1603-1617. doi: 10.1007/s00192-019-04022-8. Epub 2019 Jul 25.
3
Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Health Qual Life Outcomes. 2018 Apr 19;16(1):69. doi: 10.1186/s12955-018-0892-0.
4
A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study).
Int Urogynecol J. 2018 Feb;29(2):273-283. doi: 10.1007/s00192-017-3377-5. Epub 2017 Jun 15.
5
The effect of mirabegron on patient-related outcomes in patients with overactive bladder: the results of post hoc correlation and responder analyses using pooled data from three randomized Phase III trials.
Qual Life Res. 2015 Jul;24(7):1719-27. doi: 10.1007/s11136-014-0904-4. Epub 2015 Feb 17.
6
Overactive bladder after female genital mutilation/cutting (FGM/C) type III.
BMJ Case Rep. 2013 Oct 4;2013:bcr2012008155. doi: 10.1136/bcr-2012-008155.
7
European content validation of the Self-Assessment Goal Achievement (SAGA) questionnaire in patients with overactive bladder.
Int Urogynecol J. 2013 Sep;24(9):1529-36. doi: 10.1007/s00192-012-2039-x. Epub 2013 Apr 9.
8
A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms.
Nurs Res. 2012 Jul-Aug;61(4):283-90. doi: 10.1097/NNR.0b013e318251d8f6.
9
Patient-reported outcomes and different approaches to urinary parameters in overactive bladder: what should we measure?
Int Urogynecol J. 2012 Feb;23(2):179-92. doi: 10.1007/s00192-011-1526-9. Epub 2011 Oct 20.
本文引用的文献
1
Patient-reported reasons for discontinuing overactive bladder medication.
BJU Int. 2010 May;105(9):1276-82. doi: 10.1111/j.1464-410X.2009.09036.x. Epub 2009 Nov 12.
2
Extended-release trospium chloride improves quality of life in overactive bladder.
Value Health. 2010 Mar-Apr;13(2):251-7. doi: 10.1111/j.1524-4733.2009.00652.x. Epub 2009 Oct 8.
3
The evolution of transdermal/topical overactive bladder therapy and its benefits over oral therapy.
Rev Urol. 2009 Winter;11(1):1-6.
4
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
Int J Clin Pract. 2009 Apr;63(4):560-7. doi: 10.1111/j.1742-1241.2009.02035.x.
5
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
J Urol. 2009 Apr;181(4):1764-72. doi: 10.1016/j.juro.2008.11.125. Epub 2009 Feb 23.
6
The effects of reformulation: improved therapeutic index.
Curr Urol Rep. 2008 Nov;9(6):465-71. doi: 10.1007/s11934-008-0080-6.
7
Darifenacin treatment for overactive bladder in patients who expressed dissatisfaction with prior extended-release antimuscarinic therapy.
Int J Clin Pract. 2008 Nov;62(11):1664-74. doi: 10.1111/j.1742-1241.2008.01893.x. Epub 2008 Sep 22.
8
Long-term benefits of darifenacin treatment for patient quality of life: results from a 2-year extension study.
Neurourol Urodyn. 2008;27(6):540-7. doi: 10.1002/nau.20620.
9
Impact of fesoterodine on quality of life: pooled data from two randomized trials.
BJU Int. 2008 Jul;102(1):56-61. doi: 10.1111/j.1464-410X.2008.07710.x.
10
Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan.
J Manag Care Pharm. 2008 Apr;14(3):291-301. doi: 10.18553/jmcp.2008.14.3.291.
Zotero 插件